New poly(ADP-ribose) polymerase-1 inhibitors with antioxidant activity based on 4-carboxamidobenzimidazole-2-ylpyrroline and-tetrahydropyridine nitroxides and their precursors

Journal of Medicinal Chemistry

Volumn 52, Issue 6, 2009, Pages 1619-1629

  Kálai, Tamás ^a   Balog, Mária ^a   Szabó, Alíz ^a   Gulyás, Gergely ^a   Jekó́, József ^b   Sümegi, Balázs ^a   Hideg, Kálmán ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

^b Department of Agricultural Sciences and Environmental Management   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

2 (1 OXYL 2,2,5,5 TETRAMETHYL 2,5 DIHYDRO 1H PYRROL 3 YL) 1H BENZIMIDAZOL 4 CARBOXYLIC ACID AMIDE; 2 (1 OXYL 2,2,5,5 TETRAMETHYL 2,5 DIHYDRO 1H PYRROL 3 YLMETHYLSULFANYL) 1H BENZIMIDAZOL 4 CARBOXYLIC ACID AMIDE; 2 (1 OXYL 2,2,6,6 TETRAMETHYL 1,2,3,6 TETRAHYDROPYRIDIN 4 YLMETHYLSULFANYL) 1H BENZIMIDAZOL 4 CARBOXYLIC ACID AMIDE; 2 (2,2,5,5 TETRAMETHYL 2,5 DIHYDRO 1H PYRROL 3 YL) 1H BENZIMIDAZOL 4 CARBOXYLIC ACID AMIDE; 2 (2,2,6,6 TETRAMETHYL 1,2,3,6 TETRAHYDROPYRIDIN 4 YL) 1H BENZIMIDAZOL 4 CARBOXYLIC ACID AMIDE; 2 MERCAPTO 4 CARBOXAMIDOBENZIMIDAZOLE; AMIDE; AMINE; BENZIMIDAZOLE DERIVATIVE; NITROXIDE DERIVATIVE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG STRUCTURE; ELECTRON SPIN RESONANCE; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; URINALYSIS;

ANIMALS; ANTIOXIDANTS; CELL LINE; ELECTRON SPIN RESONANCE SPECTROSCOPY; ENZYME INHIBITORS; HUMANS; HYDROGEN BONDING; MICE; MICE, INBRED C57BL; NITROGEN OXIDES; POLY(ADP-RIBOSE) POLYMERASES; RATS;

EID: 64349113619     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm801476y     Document Type: Article

References (54)

1. Szabo, C. Cell Death: The Role of PARP; CRC Press: Boca Raton, FL, 2000.
2. Tentori, C.; Portarena, I.; Graziani, G. Potential Clinical Applications of Poly(ADP-ribose) Polymerase PARP Inhibitors. Pharamcol. Res. 2002, 45, 73-85.
3. de Murcia, C., Shall, S., Eds. From DNA Damage and Stress Signalling to Cell Death. Poly ADP-Ribolysation Reactions; Oxford University Press: Oxford, U.K., 2000.
4. Eliasson, M. J.; Sampei, K.; Mandir, A. S.; Hurn, P. D.; Traystman, R. J.; Bao, J.; Piper, A.; Wang, Z. Q.; Dawson, T. M.; Snyder, S. H.; Davson, V. L. Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia. Nat. Med. 1997, 3, 1089-1095.
5. (a) Plascke, K.; Kopitz, J.; Weigand, M. A.; Martin, E.; Bardenheuer, H. J. The neuroprotective effect of cerebral poly(ADP-ribose) poly-merase inhibition in a rat model of global ischemia. Neurosci. Lett. 2000, 248, 109-112.
6. (b) Tóth, O.; Szabó, C.; Kecskés, M.; Pótó, L.; Nagy, A.; Losonczy, H. In vitro effect of the potent poly(ADP-ribose) polymerase (PARP) inhibitor INO-1001 alone and in combination with aspirin, eptifibatide, tirofiban, enoxaparin or alteplase on haemostatic parameters. Life Sci. 2006, 79, 317-323.
7. Szabados, E.; Literati-Nagy, P.; Farkas, B.; Sumegi, B. BGP-15, a nicotinic amidoxime derivate protecting heart from ischemia reper- fusion injury through modulation of poly(ADP-ribose) polymerase. Biochem. Pharmacol. 2000, 59, 937-945.
8. + binding to poly(ADP-ribose) polymerase as derived from crystal structures and homology modeling. Biochemistry 1998, 37, 3893-3900.
9. (b) Costantino, G.; Macchiarulo, A.; Camaioni, E.; Pellicciari, R. Modelling of poly(ADP-ribose)polymerase (PARP) inhibitors. Docking of ligands and quantitative structure-activity relationship analysis. J. Med. Chem. 2001, 44, 3786-3794.
10. Banasik, M.; Komura, H.; Shimoyama, M.; Ueda, K. Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase. J. Biol. Chem. 1992, 267, 1569-1575.
11. (a) Virag, L.; Szabo, C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol. Rev. 2002, 54, 375-429.
12. (b) Pellicciari, R.; Camaioni, E.; Costantino, G. Life or death decisions: the case of poly(ADP-ribose) polymerase (PARP) as a therapeutic target for brain ischaemia. Prog. Med. Chem. 2004, 42, 125-169.
13. (c) Peukert, S.; Schwahn, U.; Güssregen, S.; Schreuder, H. E.; Hofmeister, A. Poly(ADP-ribose) polymerase (PARP-1) inhibitors based on tetrahydro-1(2H)-isoquinoline scaffold: synthesis, biological evaluation and X-ray crystal structure. Synthesis 2005, 1550-1554.
14. (d) Woon, E. C.; Threadqill, M. D. Poly(ADP-ribose)polymerase inhibition-where now? Curr. Med. Chem. 2005, 12, 2373-2392.
15. (e) Jagtap, P.; Szabó, C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat. Rev. Drug Discovery 2005, 4, 421-440.
16. (f) Horvath, E. M.; Szabo, C. Poly(ADP-ribose) polymerase as a drug target for cardiovascular disease and cancer: an update. Drug News Perspect. 2007, 20, 171-181.
17. White, A. W.; Almassy, R.; Calvert, A. H.; Curtin, N. J.; Griffin, R. J.; Hostomsky, Z.; Maegley, K.; Newell, D. R.; Srinivasan, S.; Golding, B. T. Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADR-ribose) polymerase. J. Med. Chem. 2000, 43, 4084-4097.
18. Graziani, G.; Szaboa, C. Clinical perspectives of PARP inhibitors. Pharmacol. Res. 2005, 52, 109-118.
19. Li, H.; Xu, K. Y.; Zhou, L.; Kalai, T.; Zweier, J. L.; Hideg, K.; Kuppusamy, P. A pyrroline derivative of mexiletine offers marked protection against ischemia/reperfusion-induced myocardial contractile dysfunction. J. Pharmacol. Exp. Ther. 2000, 295, 563-571.
20. (a) Kálai, T.; Várbíró, G.; Bognár, Z.; Pálfi, A.; Hantó, K.; Bognár, B.; (O″sz, E.; Sümegi, B.; Hideg, K. Synthesis and evaluation of the permeability transition inhibitory characteristics of paramagnetic and diamagnetic amiodarone derivatives. Bioorg. Med. Chem. 2005, 13, 2629-2636.
21. (b) Bognár, Z.; Kálai, T.; Pálfi, A.; Hantó, K.; Bognár, B.; Márk, L.; Szabó, Z.; Tapodi, A.; Radnai, B.; Sárszegi, Zs.; Szántó, Á., Jr.; Gallyas, F.; Hideg, K.; Sumegi, B.; Várbíró, G. A novel SOD- mimetic permeability transition inhibitor agent protects ischemic heart by inhibiting both apoptotic and nectrotic cell death. Free Radical Biol. Med. 2006, 41, 835-848.
22. (a) Kailai, T.; Khan, M.; Balog, M.; Kutala, K. V.; Kuppusamy, P.; Hideg, K. Structure- activity studies on the protection of trimetazidine derivatives modified with nitroxides and their precursor from myocardial ischemia-reperfusion injury. Bioorg. Med. Chem. 2006, 14, 5510-5516.
23. (b) Kutala, V. K.; Khan, M.; Mandal, R.; Ganesan, L. P.; Tridandapani, S.; Kálai, T.; Hideg, K.; Kuppusamy, P. Attenuation of myocardial ischemia- reperfusion injury by trimetazidine derivatives functionalized with antioxidant properties. J. Pharmacol. Exp. Ther. 2006, 317, 921-928.
24. Morphy, R.; Kay, C.; Rankovic, Z. From magic bullets to designed multiple ligands. Drug Discovery Today 2004, 9, 641-651.
25. Lam, A. M.; Pattison, D. I.; Bottle, S. E.; Keddie, J. D.; Davies, J. M. Nitric oxide and nitroxides can act as efficient scavengers of protein- derived free radicals. Chem. Res. Toxicol. 2008, 21, 2111-2119.
26. ·- or as SOD mimics? J. Biol. Chem. 1996, 271, 26026-26031.
27. Glebska, J.; Pulaski, L.; Gwozdzinski, K.; Kolimowski, J. Structure-activity relationship studies of protective function of nitroxides in Fenton system. BioMetals 2001, 14, 159-170.
28. Twomey, P.; Taira, J.; DeGraff, W.; Mitchell, J. B.; Russo, A.; Krishna, M. C.; Hankovszky, H. O.; Frank, L.; Hideg, K. Direct evidence for in vivo nitroxide free radical production from a new antiarrhythmic drug by EPR spectroscopy. Free Radical Biol. Med. 1997, 22, 909-916.
29. Bobko, A.; Kirilyuk, I. A.; Grigor'ev, I. A.; Zweier, J. L.; Khramtsov, V. V. Reversible reduction of nitroxides to hydroxilamines: roles of ascorbate and glutathione. Free Radical Biol. Med. 2007, 42, 404-412.
30. Kulcsár, Gy.; Kalai, T.; O″sz, E.; Sár, C. P.; Jeko″, J.; Sümegi, B.; Hideg, K. Synthesis and study of new 4-quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP). ARKIVOC 2003, (Part iv), 121-131.
31. Alexy, T.; Tóth, A.; Marton, Z.; Horváth, B.; Koltai, K.; Fehér, G.; Kesmarky, G.; Kálai, T.; Hideg, K.; Sümegi, B.; Tóth, K. Inhibition of ADP-evoked platelet aggregation by selected poly(ADP-ribose) polymerase Inhibitors. J. Cardiovasc. Pharmacol. 2004, 43, 423-431.
32. Barkalow, J. H.; Breting, J.; Gaede, J. B.; Haight, R. A.; Henry, R.; Kotecki, B.; Mei, J.; Pearl, K. B.; Tedrow, J. S.; Viswanath, S. K. Process development for ABT-472, a benzimidazole PARP inhibitor. Org. Process Res. Dev. 2007, 11, 693-698.
33. Bognár, B.; Kálai, T.; Hideg, K. Synthesis of benzimidazoles condensed with, or linked to, nitroxides or heterocyclic N-oxides. Synthesis 2008, 2439-2445.
34. Sár, P. C.; Kálai, T.; Bárácz, M. N.; Jerkovich, Gy.; Hideg, K. Selective reduction of nitrones and nitroxides to functionalized secondary amines. Synth. Commun. 1995, 25, 2929-2940.
35. Austen, S. C.; Kane, J. M. A. Short synthesis of the PARP inhibitor 2-(4-trifluoromethylphenyl)benzimidizal-4-carboxamide (NU1077). J Heterocycl. Chem. 2001, 38, 979-980.
36. Hideg, K.; Hankovszky, H. O.; Lex, L.; Kulcsár, Gy. Nitroxyls. VI. Synthesis and reactions of 3-hydroxymethyl-2,2,5,5-tetramethyl-2,5- dihydropyrrole-1-oxyl and 3-formyl derivatives. Synthesis 1980, 91, 1914.
37. Kálai, T.; Balog, M.; Jeko″, J.; Hideg, K. Synthesis and reactions of symmetric paramagnetic pyrrolidine diene. Synthesis 1999, 973-980.
38. Kálai, T.; Balog, M.; Jeko″, J.; Hideg, K. 3-Substituted-2,2,5,5- tetramethyl-2,5-dihydro-1H-pyrrol-1-yloxyl radicals as versatile synthones for synthesis of new paramagnetic heterocycles. Synthesis 1998, 1476-1482.
39. Kálai, T.; Balog, M.; Jeko″, J.; Hubbell, W. L.; Hideg, K. Palladium catalysed coupling reactions of paramagnetic vinyl halides. Synthesis 2002, 2365-2372.
40. Cseko, J.; Hankovszky, H. O.; Hideg, K. Synthesis of novel, highly reactive 1-oxyl-2,2,6,6-tetramethyl-1,2,5,6-tetrahydropyridine derivatives. Can. J. Chem. 1985, 63, 940-943.
41. Dreyer, J. L.; Beinert, H.; Keana, J. F. W.; Hankovszky, H. O.; Hideg, K.; Eaton, S. S.; Eaton, G. R. A spin-label study of the disposition of the Fe-S cluster with respect to the active center of aconitase. Biochim. Biovhvs. Acta 1983, 745, 229-236.
42. Krishna, M. C.; Degraff, W.; Hankovszky, H. O.; Sár, P. C.; Kálai, T.; Jekó́, J.; Russo, A.; Mitchell, J. B.; Hideg, K. Studies of structure-activity relationship of nitroxide free radicals and their precursors as modifiers against oxidative damage. J. Med. Chem. 1998, 41, 3477-3492.
43. Bottle, S. E.; Gillies, D. G.; Hughes, D. L.; Micallef, A. S.; Smirnov, A. I.; Sutcliffe, L. H. Synthesis, single crystal X-ray structure and W-band (95 GHz) EPR spectroscopy of a new anionic isoindoline aminoxyl: synthesis and characterisation of some derivatives. J. Chem. Soc., Perkin Trans. 2000, 2, 1285-1291.
44. Shvetsov, A.; Stamm, J. D.; Phillips, M.; Warshaviak, D.; Altenbach, C.; Rubenstein, P. A.; Hideg, K.; Hubbell, W. L.; Reisler, E. Conformational dynamics of loop 267-274 in G- and F-actin. Biochemistry 2006, 45, 6541-6549.
45. Kálai, T.; Jekó́, J.; Hideg, K. Synthesis of pyrroline nitroxide annulated carbocycles and heterocycles. Synthesis 2000, 831-837.
46. Hankovszky, H. O.; Hideg, K.; Lex, L. Nitroxyls. VII. Synthesis and reactions of highly reactive 1-oxyl-2,2,5,5-tetramethyl-2,5-dihydro- pyrrole-3-ylmethyl sulfonates. Synthesis 1980, 914-916.
47. Arienti, K. L.; Brunmark, A.; Axe, F. U.; McClure, K.; Lee, A.; Blevitt, J.; Neff, K. D.; Huang, L.; Crawford, S.; Pandit, C. R.; Karlsson, L.; Breitenbucher, J. G. Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles. J. Med. Chem. 2005, 48, 1873-1885.
48. (a) Nishimura-Suzuki, T.; Swartz, H. M. Characterization of redox activity in resting and activated mast cells by reduction and reoxidation of lipophylic nitroxides. Gen. Pharmacol. 1998, 3, 617-623.
49. (b) Dikalov, S.; Skatchkov, M.; Fink, B.; Bassenge, E. Quantification of superoxide radicals and peroxinitrite in vascular cells using oxidation of sterically hindered hydroxylamines and electron spin resonance. Nitric Oxide: Biol. Chem. 1997, 1, 423-431.
50. Saito, K.; Takeshita, K.; Anzai, K.; Ozawa, T. Pharmacokinetic study of acyl-protected hydroxylamine probe, 1-acetoxy-3-carbabamoyl-2,2,5,5- tetramethylpyrrolidine, for in vivo measurements of reactive oxygen species. Free Radical Biol. Med. 2004, 36, 517-525.
51. Hideg, K.; Kálai, T.; Sümegi, B. New Alicyclic-Amine- Substituted 4-Carboxamidobenzimidazoles as PARP-Inhibitors and Antioxidants. Patent WO2004/096793 A1, 2004.
52. Pennign, D. T.; Zhu, G.-D.; Gandhi, V. B.; Gong, J.; Thomas, S.; Luzbisch, W.; Grandel, R.; Wernet, W.; Park, C. H.; Fry, E. H.; Liu, X.; Shi, Y.; Kléinghofer, V.; Johnson, E. F.; Donawho, C. K.; Frost, D. J.; Bontcheva-Diaz, V.; Bouska, J. J.; Olson, A. M.; Marsh, K. C.; Luo, Y.; Rosenberg, S. H.; Giranda, L. V. Discovery and SAR of 2(-1-propynilpiperidin-4- yl)-1//-benzirmdazole-4-carboxarnide: a potent inhibitor of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer. Bioorg. Med. Chem. 2008, 16, 6965-6975.
53. Shah, G. M.; Poirier, D.; Duchaine, C.; Brochu, G.; Desnoyers, S.; Lagueux, J.; Verreault, A.; Hoflack, J. C.; Kirkland, J. B.; Poirier, G. G. Methods for biochemical study of poly(ADP-ribose) metabolism in vitro and in vivo. Anal. Biochem. 1995, 227, 1-13.
54. Miles, A. M.; Bohle, D. S.; Glassbrenner, P. A.; Hansert, B.; Wink, D. A.; Grisham, M. B. Modulation of superoxide-dependent oxidation and hydroxylation reactions by nitric oxide. J. Biol. Chem. 1996, 277, 40-47.